UPDATE: Incyte, Courting New Role as Drug Developer, Names New CEO, President, and CSO | GenomeWeb

SAN FRANCISCO, Nov. 28 – Reaction to Incyte Genomics’ Monday announcement appointing a new CEO and president, a move that underscores Incyte's intent to move from a genomics database provider to a drug developer, has been positive but also “wait and see.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.